![]() ![]() ![]() Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. ![]() Repurchased over 1.8 million shares of common stock at an aggregate cost of $74.3 million under the stock repurchase program announced in March 2022ġ) Core Revenue excludes revenue from COVID-19 testing products and services including COVID-19 NGS testing revenue. Non-GAAP income of $179.4 million, or $5.79 per share GAAP income of $143.4 million, or $4.63 per share Repurchased approximately 815,000 shares of common stock at an aggregate cost of $29.1 million under the stock repurchase program announced in March 2022Ĭore Revenue 1 grew 95% year-over-year to $181.5 million Non-GAAP loss of $14.2 million, or $0.48 per shareĬash, cash equivalents, and investments in marketable securities, including investments pending settlement, of $872.0 million as of December 31, 2022 GAAP loss of $23.8 million, or $0.80 per share (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.Ĭore Revenue 1 grew 97% year-over-year to $55.0 million Full Year 2022 Total Revenue of $619.0 million Q4 Total Revenue of $67.7 millionįull Year 2022 Core Revenue grows 95% year-over-year to $181.5 million Q4 Core Revenue grows 97% year-over-year to $55.0 million ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |